Novo Nordisk A/S (NVO) Stock Forecast & Price Target

$117.81

+2.69 (+2.34%)

(As of 10/7/2024 ET)

Novo Nordisk A/S - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 7 Analyst Ratings

Sell
0

Hold
1

Buy
6

Based on 7 Wall Street analysts who have issued ratings for Novo Nordisk A/S in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 7 analysts, 1 has given a hold rating, and 6 have given a buy rating for NVO.

Consensus Price Target

$145.17
23.22% Upside

According to the 7 analysts' twelve-month price targets for Novo Nordisk A/S, the average price target is $145.17. The highest price target for NVO is $160.00, while the lowest price target for NVO is $115.00. The average price target represents a forecasted upside of 23.22% from the current price of $117.81.

Get the Latest News and Ratings for NVO and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Novo Nordisk A/S and its competitors.

NVO Analyst Ratings Over Time

Type	Current Forecast 10/8/23 to 10/7/24	1 Month Ago 9/8/23 to 9/7/24	3 Months Ago 7/10/23 to 7/9/24	1 Year Ago 10/8/22 to 10/8/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	6 Buy rating(s)	6 Buy rating(s)	7 Buy rating(s)	3 Buy rating(s)
Hold	1 Hold rating(s)	1 Hold rating(s)	2 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$145.17	$145.17	$145.67	$60.83
Forecasted Upside	23.22% Upside	10.70% Upside	3.74% Upside	-33.96% Downside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

[SHOCKING] Crypto Document Leak… (Ad)

The crypto market waits for no one. And my team of experts and I believe that a BIG move is right around the corner. That's why we're offering you instant access to the game-changing book that's transforming average investors into massive crypto successes.

Download your digital copy now

NVO Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

NVO Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Novo Nordisk A/S Stock vs. The Competition

Type	Novo Nordisk A/S	Medical Companies	S&P 500
Consensus Rating Score	2.86	2.78	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	23.41% Upside	12,688.61% Upside	8.01% Upside
News Sentiment Rating	Positive News See Recent NVO News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Action	Rating	Price Target	Upside/Downside on Report Date
9/16/2024	Cantor Fitzgerald 3 of 5 stars	Reiterated Rating	Overweight ➝ Overweight	$160.00 ➝ $160.00	+16.67%
8/8/2024	BMO Capital Markets 4 of 5 stars	Lower Target	Outperform ➝ Outperform	$170.00 ➝ $160.00	+27.79%
6/10/2024	Argus 3 of 5 stars	Boost Target	Buy ➝ Buy	$125.00 ➝ $160.00	+13.09%
5/30/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$156.00	+17.58%
1/23/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$120.00	+13.75%
1/16/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral
Get the Latest News and Ratings for NVO and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Novo Nordisk A/S and its competitors with MarketBeat's FREE daily newsletter.
12/4/2023	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$105.00 ➝ $115.00	+14.19%
8/11/2023	DNB Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
7/14/2023	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
4/13/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Outperform
12/12/2022	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target		$32.50 ➝ $36.25	+11.94%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 12:41 AM ET.

Should I Buy Novo Nordisk A/S Stock? NVO Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, October 6, 2024. Please send any questions or comments about these Novo Nordisk A/S pros and cons to contact@marketbeat.com.

Novo Nordisk A/S
Bull Case

Here are some ways that investors could benefit from investing in Novo Nordisk:

Novo Nordisk's stock price has shown resilience despite recent market fluctuations, indicating stability.
Continued strong financial performance with a high return on equity of 87.43%, showcasing profitability.
Positive analyst ratings and forecasts, with a consensus price target of $145.17, suggesting growth potential.
Robust revenue generation, reporting $9.82 billion in revenue for the last quarter, demonstrating strong sales.
Market capitalization of $534.24 billion, reflecting the company's significant size and market presence.

Novo Nordisk A/S
Bear Case

Investors should be bearish about investing in Novo Nordisk for these reasons:

Recent decline in Novo Nordisk's share price by 2.5%, indicating short-term volatility.
Debt-to-equity ratio of 0.46, which may raise concerns about the company's leverage levels.
Lower-than-expected earnings per share of $0.65 for the last quarter, missing the consensus estimate by ($0.06).
Current price-to-earnings ratio of 41.05, potentially signaling overvaluation compared to industry peers.
Decrease in trading volume by 52% from the average session volume, suggesting reduced investor interest.

NVO Forecast - Frequently Asked Questions

: According to the research reports of 7 Wall Street equities research analysts, the average twelve-month stock price forecast for Novo Nordisk A/S is $145.17, with a high forecast of $160.00 and a low forecast of $115.00.
: 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novo Nordisk A/S in the last twelve months. There is currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" NVO shares.
: According to analysts, Novo Nordisk A/S's stock has a predicted upside of 23.22% based on their 12-month stock forecasts.
: Novo Nordisk A/S has been rated by research analysts at BMO Capital Markets, and Cantor Fitzgerald in the past 90 days.
: Analysts like Novo Nordisk A/S more than other "medical" companies. The consensus rating score for Novo Nordisk A/S is 2.86 while the average consensus rating score for "medical" companies is 2.78. Learn more on how NVO compares to other companies.

Stock Forecasts and Research Tools

Related Companies:

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

U.S. Stock Market Now on Verge of Collapse (Ad)

"Wheels Are Falling Off" The U.S. Stock Market Today, analyst Dan Ferris is back issuing a new warning. He says what's coming next to the U.S. economy could be much worse than anything he's predicted before. And this time, he says, "The trouble is coming straight for Nvidia and the AI market."

Click here to see why.

This page (NYSE:NVO) was last updated on 10/7/2024 by MarketBeat.com Staff

From Our Partners